A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis

The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo

Inclusion

• relapsing-remitting MS
• at least 1 exacerbation in preceding 2 years
• at least 1 MRI lesion
• stable for 2 months prior to dosing

Exclusion

• progressive MS
• currently treated with an immunomodulatory therapy
• previously treated with an approved MS drug where treatment was discontinued for lack of efficacy
• active bacterial or viral infections